Synopsis
Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
2. Azopt
1. 138890-62-7
2. Azopt
3. Al-4862
4. Al 4862
5. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
6. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
7. 138890-50-3
8. Chebi:3176
9. (r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
10. Nsc-760050
11. (+)-4-ethylamino-3,4-dihydro-2-(methoxy)propyl-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide
12. (r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
13. (r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
14. 2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (r)-
15. Brinzolamide [usan]
16. Mfcd08067749
17. Dsstox_cid_25531
18. Dsstox_rid_80934
19. Dsstox_gsid_45531
20. 2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (4r)-
21. Bz1
22. 9451z89515
23. (4r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
24. Brinzolamide (brz)
25. Azopt (tn)
26. Brinzolamide (jan/usp/inn)
27. 3znc
28. Ncgc00016979-01
29. Brinzolamide [usan:usp:inn:ban]
30. Unii-9451z89515
31. Brinzolamide- Bio-x
32. Cas-138890-62-7
33. Prestwick0_000365
34. Prestwick1_000365
35. Prestwick2_000365
36. Prestwick3_000365
37. Brinzolamide [mi]
38. Brinzolamide [inn]
39. Brinzolamide [jan]
40. Brinzolamide [vandf]
41. Schembl24636
42. Brinzolamide [mart.]
43. Bspbio_000489
44. Mls002153787
45. Bidd:gt0039
46. Brinzolamide [usp-rs]
47. Brinzolamide [who-dd]
48. Spbio_002410
49. Amy372
50. Bpbio1_000539
51. Chembl220491
52. Gtpl6797
53. Brinzolamide [ema Epar]
54. Dtxsid6045531
55. Bdbm10885
56. Brinzolamide, >=98% (hplc)
57. Brinzolamide [orange Book]
58. Hms1569i11
59. Hms2096i11
60. Hms2234k06
61. Hms3713i11
62. Hms3885i11
63. Brinzolamide [usp Impurity]
64. Azarga Component Brinzolamide
65. Bcp22330
66. Hy-b0588
67. Zinc3953037
68. Brinzolamide [usp Monograph]
69. Tox21_110722
70. S3178
71. Akos005145708
72. Simbrinza Component Brinzolamide
73. Tox21_110722_1
74. Ac-5277
75. Brinzolamide Component Of Azarga
76. Ccg-220365
77. Ccg-222516
78. Db01194
79. Nsc 760050
80. Ncgc00179542-03
81. Ncgc00179542-09
82. Ncgc00179542-10
83. As-35084
84. Bb164262
85. Brinzolamide Component Of Simbrinza
86. Smr001233169
87. Ab00513824
88. B4258
89. Sw197152-3
90. Al4862;al 4862;al-4862
91. C07760
92. D00652
93. Ab00513824_06
94. Q411517
95. Sr-01000838832
96. Q-200751
97. Sr-01000838832-2
98. Brd-k74913225-001-03-3
99. Brinzolamide, United States Pharmacopeia (usp) Reference Standard
100. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2h,3h,4h-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide
101. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2h,3h,4h-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide
102. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide-1,1-dioxide
103. (4r)-4-ethylamino-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[4,5-e]thiazine-6-sulfonamide
104. (5r)-5-ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2,9-dithia-3-azabicyclo[4.3.0]nona-1(6)7-diene-8-sulfonamide
105. (r)-3,4-dihydro-4-ethylamino-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide
| Molecular Weight | 383.5 g/mol |
|---|---|
| Molecular Formula | C12H21N3O5S3 |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 383.06433430 g/mol |
| Monoisotopic Mass | 383.06433430 g/mol |
| Topological Polar Surface Area | 164 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 598 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Azopt |
| PubMed Health | Brinzolamide (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor formulated for multidose topical ophthalmic use. Brinzolamide is described chemically as: (R)-(+)-4-Ethylamino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno [3,2-e]-1... |
| Active Ingredient | Brinzolamide |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 1% |
| Market Status | Prescription |
| Company | Alcon Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Azopt |
| PubMed Health | Brinzolamide (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor formulated for multidose topical ophthalmic use. Brinzolamide is described chemically as: (R)-(+)-4-Ethylamino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno [3,2-e]-1... |
| Active Ingredient | Brinzolamide |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 1% |
| Market Status | Prescription |
| Company | Alcon Pharms |
For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
FDA Label
Azopt is indicated to decrease elevated intraocular pressure in:
- ocular hypertension;
- open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.
Used in the treatment of glaucoma, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Brinzolamide can decrease intraocular pressure by approximately 16-19% in patients with elevated intraocular pressure.
Carbonic Anhydrase Inhibitors
A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. (See all compounds classified as Carbonic Anhydrase Inhibitors.)
S01EC04
S01EC04
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
S - Sensory organs
S01 - Ophthalmologicals
S01E - Antiglaucoma preparations and miotics
S01EC - Carbonic anhydrase inhibitors
S01EC04 - Brinzolamide
Absorption
Absorbed into systemic circulation following topical ocular application
Ophthalmic
111 days
Brinzolamide is a highly specific inhibitor of CA-II, which is the main CA isoenzyme involved in the secretion of aqueous humor. Inhibition of CA in the ciliary process of the eye slows the formation of bicarbonate, and reduces sodium and fluid transport. This results in a reduction in the rate of aqueous humor secretion and the intraocular pressure. Brinzolamide is absorbed systemically following topical ocular administration. Since it has a high affinity for CA-II, brinzolamide binds extensively to red blood cells, where CA-II is primarily found. As sufficient CA-II activity remains, adverse effects resulting from the systemic inhibition of CA by brinzolamide are not observed. The metabolite N-desethyl brinzolamide is also formed. This metabolite binds to CA and accumulates in red blood cells as well. In the presence of brinzolamide, the metabolite binds mainly to carbonic anhydrase I (CA-I).
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
Registrant Name : Novartis Korea Co., Ltd.
Registration Date : 2025-12-05
Registration Number : 20240322-209-J-1624(1)
Manufacturer Name : SCI Pharmtech, Inc.
Manufacturer Address : No.61, Ln.309, Haihu N. Rd., Luzhu Dist., Taoyuan City 33856, Taiwan
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2024-03-22
Registration Number : 20240322-209-J-1624
Manufacturer Name : SCI Pharmtech, Inc.
Manufacturer Address : No.61, Ln.309, Haihu N. Rd., Luzhu Dist., Taoyuan City 33856, Taiwan
Registrant Name : Novartis Korea Co., Ltd.
Registration Date : 2023-10-10
Registration Number : 20231010-209-J-1549
Manufacturer Name : Finorga SAS
Manufacturer Address : route de Givors, Chasse Sur Rhone, 38670, France
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2022-07-28
Registration Number : 20220728-209-J-1261
Manufacturer Name : Duke Chem, SA
Manufacturer Address : Pol. Industrial Sant Pere Molanta, Avgda. Mare de Déu de Montserrat, 93-99, Olèrdol...
Registrant Name : Iksoo Pharmaceutical Co., Ltd.
Registration Date : 2021-10-25
Registration Number : 20211025-209-J-839
Manufacturer Name : Biocon Limited@Microtrol Ste...
Manufacturer Address : Plot No. 213 – 215 and 216/B, Phase - II, IDA, Pashamylaram, Sangareddy District-50...

Registrant Name : Taejun Pharmaceutical Co., Ltd.
Registration Date : 2025-11-12
Registration Number : 20211025-209-J-839(1)
Manufacturer Name : Biocon Limited@Microtrol Ste...
Manufacturer Address : Plot No. 213 – 215 and 216/B Phase-II, IDA, Pashamylaram, Sangareddy District-502 3...

Registrant Name : Novartis Korea Co., Ltd.
Registration Date : 2023-10-10
Registration Number : 20231010-209-J-1548
Manufacturer Name : Carbogen AMCIS AG
Manufacturer Address : Hauptstrasse 171, 4416 Bubendorf, Switzerland

Registrant Name : Eltek Pharmachem Co., Ltd.
Registration Date : 2023-01-04
Registration Number : 20230104-209-J-1431
Manufacturer Name : Micro Labs Limited
Manufacturer Address : Plot No.43-45, KIADB, Bommasandra, Industrial Area, 4th Phase Anekal Taluk, Bengaluru...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.
About the Company : Gentec Pharmaceutical Group, with over 40 years of experience, is a leader in raw materials and ingredients for food, dietary, and nutrition sectors. It manufactures and commercial...
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
About the Company : SCI Pharmtech Inc. offers APIs, advanced intermediates, and custom products with a focus on rapid development and cost-effective production. Its fully equipped research labs, pilot...
About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
About the Company : Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and r...
Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.
About the Company : Bhavna Laboratories Pvt. Ltd., founded in 1986, is an Indian manufacturer of APIs and intermediates. The company is approved by the FDA of India and holds cGMP certification for it...
Century has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.
About the Company : Century Pharmaceuticals, established in 1982, has 40 years of experience manufacturing APIs for major pharma companies in India and abroad. Its products are made in compliance with...
About the Company : Neuland Laboratories, established in 1984 and headquartered in Hyderabad, is a publicly listed company offering solutions for pharmaceutical chemistry needs—from library compound...
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
About the Company : Pharmathen, established in 1969, has emerged as a leading in-house development partner in Europe. It specializes in the development, registration, manufacturing & life-cycle manage...
Capital Farma, a leading European pharmaceutical company focusing on the development & distribution of niche APIs & Pharma Services.
About the Company : Capital Farma provides integrated pharmaceutical solutions with a focus on high-quality Active Pharmaceutical Ingredients (APIs) sourced from leading European manufacturers. The co...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma, Open-Angle.
Lead Product(s): Brinzolamide,Brimonidine Tartrate,Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Sengi
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2025

Lead Product(s) : Brinzolamide,Brimonidine Tartrate,Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Sengi
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
Details : Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brinzolamide, generic equivalent to the Reference Listed Drug Azopt Ophthalmic Suspension, is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma.
Lead Product(s): Brinzolamide,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Azopt-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 13, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brinzolamide,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Padagis Announces the Launch of Brinzolamide Ophthalmic Suspension with CGT Exclusivity
Details : Brinzolamide, generic equivalent to the Reference Listed Drug Azopt Ophthalmic Suspension, is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma.
Product Name : Azopt-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.
Lead Product(s): Brinzolamide,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brinzolamide,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.
Lead Product(s): Brinzolamide,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 29, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brinzolamide,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Simbrinza is a fixed combination of a carbonic anhydrase inhibitor and an alpha-2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Brinzolamide,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Simbrinza
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Alcon Inc
Deal Size: $355.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 28, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brinzolamide,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Alcon Inc
Deal Size : $355.0 million
Deal Type : Acquisition
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Details : Simbrinza is a fixed combination of a carbonic anhydrase inhibitor and an alpha-2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Product Name : Simbrinza
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 28, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Teva announced launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma.
Lead Product(s): Brinzolamide,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brinzolamide,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Teva announced launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.
Lead Product(s): Brimonidine Tartrate,Brinzolamide
Therapeutic Area: Ophthalmology Brand Name: Ailamide
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Otsuka Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 16, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brimonidine Tartrate,Brinzolamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.
Product Name : Ailamide
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 16, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.
Lead Product(s): Brinzolamide,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brinzolamide,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glaucoma.
Lead Product(s): Brinzolamide,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brinzolamide,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
Details : Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glaucoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma.
Lead Product(s): Brinzolamide,Brimonidine Tartrate,Travoprost
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brinzolamide,Brimonidine Tartrate,Travoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2017

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results](S)-3,4-dihydro-6-chloro-4- hydroxy-2H-thieno[3,2-...
CAS Number : 160982-16-1
End Use API : Brinzolamide
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM se...
(S)-3,4-Dihydro-4-hydroxy-2-(3- methoxypropyl)-2H-...
CAS Number : 154127-42-1
End Use API : Brinzolamide
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM se...
2,5-dichloro-3-acetyl thiophene
CAS Number : 36157-40-1
End Use API : Brinzolamide
About The Company : Indian Drugs And Chemicals supplies quality products using modern technologies, supported by strong industry expertise. The company serves global markets with a...
3-Acetyl-5-chloro-2-thiophenesulfonamide
CAS Number : 160982-10-5
End Use API : Brinzolamide
About The Company : The Bakul Group of companies headquartered in Mumbai, India are engaged in the development and manufacture of high-quality Active Pharmaceutical Ingredients (AP...

3-Bromoacetyl-5-chloro-2-thiophene sulfonamide
CAS Number : 160982-11-6
End Use API : Brinzolamide
About The Company : The Bakul Group of companies headquartered in Mumbai, India are engaged in the development and manufacture of high-quality Active Pharmaceutical Ingredients (AP...

6-Chloro-2,3-dihydro-4H-thieno[3,2-e]-1,2-thiazin-...
CAS Number : 174139-69-6
End Use API : Brinzolamide
About The Company : The Bakul Group of companies headquartered in Mumbai, India are engaged in the development and manufacture of high-quality Active Pharmaceutical Ingredients (AP...

(S)-6-Chloro-4-hydroxy-3,4-dihydro-2H-thieno[3,2-e...
CAS Number : 160982-16-1
End Use API : Brinzolamide
About The Company : The Bakul Group of companies headquartered in Mumbai, India are engaged in the development and manufacture of high-quality Active Pharmaceutical Ingredients (AP...

CAS Number : 36865-41-5
End Use API : Brinzolamide
About The Company : Berr Chemical Company Ltd is a high-tech enterprise engaged in Pharmaceuctials; azepan products;Pyrimidine products;Piperazines products;Pyridine products;Piper...

3-Acetyl-5-chloro-2-thiophenesulfonamide
CAS Number : 160982-10-5
End Use API : Brinzolamide
About The Company : Green Stone Swiss Co ., ltd.is a high-tech enterprise of pharmaceuticals and health ingredients, and provide customized products/OEM/ODM. We signed technical co...

3-(2-Bromoacetyl)-5-chloro-2-thiophenesulfonami de
CAS Number : 160982-11-6
End Use API : Brinzolamide
About The Company : Green Stone Swiss Co ., ltd.is a high-tech enterprise of pharmaceuticals and health ingredients, and provide customized products/OEM/ODM. We signed technical co...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info :
Registration Country : India
Brand Name : Brinzolamide
Dosage Form : Nano particles
Dosage Strength : 1%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Packaging :
Regulatory Info :
Dosage : Nano particles
Dosage Strength : 1%
Brand Name : Brinzolamide
Approval Date :
Application Number :
Registration Country : India
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info :
Registration Country : Greece
Brinzolamide; Brimonidine Tartrate
Brand Name :
Dosage Form : Eye Drops Suspension
Dosage Strength : 2MG/ML; 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info :
Brinzolamide; Brimonidine Tartrate
Dosage : Eye Drops Suspension
Dosage Strength : 2MG/ML; 10MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info :
Registration Country : Greece
Brand Name :
Dosage Form : Eye Drops Suspension
Dosage Strength : 5MG/ML; 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info :
Dosage : Eye Drops Suspension
Dosage Strength : 5MG/ML; 10MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : EU Approved
Registration Country : Greece
Brand Name :
Dosage Form : Eye Drops Suspension
Dosage Strength : 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Approved
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : EU Approved
Dosage : Eye Drops Suspension
Dosage Strength : 10MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Eye Drops Suspension
Dosage Strength : 10MG/ML
Packaging : Multi Dose Container
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging : Multi Dose Container
Regulatory Info : USA
Dosage : Eye Drops Suspension
Dosage Strength : 10MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Ophthalmic Suspension
Dosage Strength : 1.0%/W/V
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Ophthalmic Suspension
Dosage Strength : 1.0%/W/V
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Suspension
Dosage Strength : 1%
Packaging : 5/10/15ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging : 5/10/15ml
Regulatory Info : Generic
Dosage : Suspension
Dosage Strength : 1%
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : India
Brimonidine Tartrate; Brinzolamide
Brand Name :
Dosage Form : Ophthalmic Solution
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info : Generic
Brimonidine Tartrate; Brinzolamide
Dosage : Ophthalmic Solution
Dosage Strength :
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Nano Particles For Oph...
Dosage Strength : 1%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Nano Particles For Oph...
Dosage Strength : 1%
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Bangladesh
Brand Name : BNZ
Dosage Form : Eye Drop
Dosage Strength : 1%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Bangladesh

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Eye Drop
Dosage Strength : 1%
Brand Name : BNZ
Approval Date :
Application Number :
Registration Country : Bangladesh

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
13 Feb 2024
Reply
06 Feb 2023
Reply
13 Jan 2023
Reply
28 Apr 2022
Reply
25 Feb 2022
Reply
02 Feb 2022
Reply
10 Jan 2022
Reply
06 Dec 2021
Reply
06 Dec 2021
Reply
15 Jun 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
21
PharmaCompass offers a list of Brinzolamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Brinzolamide manufacturer or Brinzolamide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Brinzolamide manufacturer or Brinzolamide supplier.
PharmaCompass also assists you with knowing the Brinzolamide API Price utilized in the formulation of products. Brinzolamide API Price is not always fixed or binding as the Brinzolamide Price is obtained through a variety of data sources. The Brinzolamide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Brinzolamide (BRZ) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Brinzolamide (BRZ), including repackagers and relabelers. The FDA regulates Brinzolamide (BRZ) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Brinzolamide (BRZ) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Brinzolamide (BRZ) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Brinzolamide (BRZ) supplier is an individual or a company that provides Brinzolamide (BRZ) active pharmaceutical ingredient (API) or Brinzolamide (BRZ) finished formulations upon request. The Brinzolamide (BRZ) suppliers may include Brinzolamide (BRZ) API manufacturers, exporters, distributors and traders.
click here to find a list of Brinzolamide (BRZ) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Brinzolamide (BRZ) DMF (Drug Master File) is a document detailing the whole manufacturing process of Brinzolamide (BRZ) active pharmaceutical ingredient (API) in detail. Different forms of Brinzolamide (BRZ) DMFs exist exist since differing nations have different regulations, such as Brinzolamide (BRZ) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Brinzolamide (BRZ) DMF submitted to regulatory agencies in the US is known as a USDMF. Brinzolamide (BRZ) USDMF includes data on Brinzolamide (BRZ)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Brinzolamide (BRZ) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Brinzolamide (BRZ) suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Brinzolamide (BRZ) Drug Master File in Japan (Brinzolamide (BRZ) JDMF) empowers Brinzolamide (BRZ) API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Brinzolamide (BRZ) JDMF during the approval evaluation for pharmaceutical products. At the time of Brinzolamide (BRZ) JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Brinzolamide (BRZ) suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Brinzolamide (BRZ) Drug Master File in Korea (Brinzolamide (BRZ) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Brinzolamide (BRZ). The MFDS reviews the Brinzolamide (BRZ) KDMF as part of the drug registration process and uses the information provided in the Brinzolamide (BRZ) KDMF to evaluate the safety and efficacy of the drug.
After submitting a Brinzolamide (BRZ) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Brinzolamide (BRZ) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Brinzolamide (BRZ) suppliers with KDMF on PharmaCompass.
A Brinzolamide (BRZ) written confirmation (Brinzolamide (BRZ) WC) is an official document issued by a regulatory agency to a Brinzolamide (BRZ) manufacturer, verifying that the manufacturing facility of a Brinzolamide (BRZ) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Brinzolamide (BRZ) APIs or Brinzolamide (BRZ) finished pharmaceutical products to another nation, regulatory agencies frequently require a Brinzolamide (BRZ) WC (written confirmation) as part of the regulatory process.
click here to find a list of Brinzolamide (BRZ) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Brinzolamide (BRZ) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Brinzolamide (BRZ) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Brinzolamide (BRZ) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Brinzolamide (BRZ) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Brinzolamide (BRZ) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Brinzolamide (BRZ) suppliers with NDC on PharmaCompass.
Brinzolamide (BRZ) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Brinzolamide (BRZ) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Brinzolamide (BRZ) GMP manufacturer or Brinzolamide (BRZ) GMP API supplier for your needs.
A Brinzolamide (BRZ) CoA (Certificate of Analysis) is a formal document that attests to Brinzolamide (BRZ)'s compliance with Brinzolamide (BRZ) specifications and serves as a tool for batch-level quality control.
Brinzolamide (BRZ) CoA mostly includes findings from lab analyses of a specific batch. For each Brinzolamide (BRZ) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Brinzolamide (BRZ) may be tested according to a variety of international standards, such as European Pharmacopoeia (Brinzolamide (BRZ) EP), Brinzolamide (BRZ) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Brinzolamide (BRZ) USP).